Keywords
Bone cancer
Breast Cancer
General Oncology
Gynecological Cancers
Head and neck cancer
Lung Cancer
Radiation Oncology
Authors:
Quande Lin
The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China
Correspondence to Author: Quande Lin
Abstract:
During the past few years, patients with relapsed or refractory multiple myeloma (RRMM) have been treated using bispecific antibodies (BsAbs) and dual-targeted chimeric antigen receptor T (CAR T) cells, as more and more patients were not adequately helped by at least three prior rounds of therapy. The most common combos are GPRC5D/CD3 and BCMA/CD3. According to clinical results, patients are more likely to experience stronger and longer-lasting responses. Here, we present the most recent information on BsAbs that target BCMA/CD3, GPRC5D/CD3, and BCMA/CD19 CAR T cells, as presented at the ASCO annual meeting in 2023.
Keywords:
Multiple myeloma, Bispecific antibody, CAR T, Clinical trial
Citation:
Quande Lin. Dual-targeting CAR-T cells and bispecific antibodies for multiple myeloma. World Journal of Medical Oncology 2023
Journal Info
- Journal Name: World Journal of Medical Oncology
- Impact Factor: 2.709**
- ISSN: 2766-6077
- DOI: 10.52338/wjoncgy
- Short Name: WJMOY
- Acceptance rate: 55%
- Volume: 6 (2024)
- Submission to acceptance: 25 days
- Acceptance to publication: 10 days
INDEXING
OUR PUBLICATION BENEFITS
- International Reach
- Peer Review
- Rapid Publication
- Open Access
- High Visibility